Recurrent Head and Neck Cancer Clinical Trial
Official title:
Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill more tumor cells. It is not yet known whether docetaxel is more effective with or without gefitinib in treating head and neck cancer. This randomized phase III trial is studying docetaxel and gefitinib to see how well they work compared to docetaxel alone in treating patients with metastatic or locally recurrent head and neck cancer.
PRIMARY OBJECTIVES:
I. To determine the survival of poor prognosis patients with recurrent/metastatic squamous
cell carcinoma of the head and neck treated with docetaxel with or without ZD1839 (Iressa,
gefitinib).
SECONDARY OBJECTIVES:
I. To determine the time to progression and response rate in poor prognosis patients with
recurrent/metastatic squamous cell carcinoma of the head and neck treated with docetaxel
with or without ZD1839 (Iressa, gefitinib).
II. To correlate the expression and activation status of the epidermal growth factor
receptor (EGFR) signaling pathway with clinical outcome in the above patient population. The
following specific biomarkers will be measured by immunohistochemistry on paraffin-embedded
tumor tissue: EGFR, p-EGFR, AKT, p-AKT, Transforming growth factor (TGF)-alpha, Ki-67,
extracellular-signal-regulated kinase (ERK), p-ERK, p70s6, p- p70s6 , and p27.
III. To evaluate the frequency of common polymorphisms of Cytochrome P450 3A (CYP3A) and
EGFR in this study population and the impact of these polymorphisms on survival, time to
progression, response rate, and toxicities.
IV. To analyze docetaxel and ZD1839 (Iressa, gefitinib) pharmacokinetics and to correlate
polymorphisms with pharmacokinetic variability, response, toxicity, and other endpoints.
V. To evaluate disease-related symptoms and overall quality of life among patients receiving
docetaxel only to those receiving docetaxel and ZD1839 (Iressa, gefitinib).
VI. To evaluate whether additional clinical benefit associated with ZD1839 (Iressa,
gefitinib) can be detected as an improvement in patient-reported symptoms on the FACT Head
and Neck Symptom Index (FHNSI)-10 and GP5.
OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients
are stratified according to treatment with prior chemotherapy (pretreated vs untreated),
Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1 vs 2), weight loss
within the past 6 months (< 5% vs ≥ 5%), and prior cetuximab treatment (yes or no). Patients
are randomized to 1 of 2 treatment arms.
Arm I: Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15
and oral placebo once daily on days 1-28.
Arm II: Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity. Patients in arm I who have disease progression may receive
single-agent oral gefitinib once daily until further disease progression (which is called
step 2 in the study).
Quality of life is assessed at baseline, on days 15 and 28 of course 1, on day 28 of all
subsequent courses, and at 2-4 weeks after completion of study treatment.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 330 patients (165 per treatment arm) will be accrued for this
study within 31.5 months.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05738187 -
Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study
|
N/A | |
Recruiting |
NCT02567383 -
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05980000 -
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03691714 -
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02842125 -
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT04969861 -
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04260126 -
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
|
Phase 2 | |
Completed |
NCT02358031 -
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
|
Phase 3 | |
Completed |
NCT02422979 -
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04902027 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers
|
Phase 1 | |
Recruiting |
NCT04534205 -
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
|
Phase 2 | |
Active, not recruiting |
NCT02289209 -
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT06239220 -
PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
|
Phase 2 | |
Recruiting |
NCT04673929 -
Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
|
||
Recruiting |
NCT03754933 -
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT03937141 -
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT01606566 -
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
|
Phase 2 | |
Completed |
NCT01620242 -
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
|
Phase 2 | |
Completed |
NCT01255800 -
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
|
Phase 1 |